Piramal Pharma Limited (NSE:PPLPHARMA)
India · Delayed Price · Currency is INR 190.65
-6.38 (-3.24%)
Aug 1, 2025, 3:30 PM IST
Verve Therapeutics Revenue
Piramal Pharma had revenue of 19.34B INR in the quarter ending June 30, 2025, a decrease of -0.89%. This brings the company's revenue in the last twelve months to 91.34B, up 9.08% year-over-year. In the fiscal year ending March 31, 2025, Piramal Pharma had annual revenue of 91.51B with 11.99% growth.
Revenue (ttm)
91.34B
Revenue Growth
+9.08%
P/S Ratio
2.77
Revenue / Employee
16.68M
Employees
5,476
Market Cap
253.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 91.51B | 9.80B | 11.99% |
| Mar 31, 2024 | 81.71B | 10.90B | 15.39% |
| Mar 31, 2023 | 70.82B | 3.47B | 5.16% |
| Mar 31, 2022 | 67.34B | 8.47B | 14.39% |
| Mar 31, 2021 | 58.87B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 93.60B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 232.42B |
| Fortis Healthcare | 77.86B |
| Aurobindo Pharma | 317.24B |